Haleon Analyst Price Targets - Benzinga

Haleon PLC

HLNNYSE

Trade with Public

Trade with Public

$9.60

-0.26-2.64%

Últ. Act.: Sep 4, 9:30 AM

Panorámica general Noticias Previsión de beneficiosPrecios objetivoFinanzas Sentimiento Propiedad Dividendos Comparar Opciones Informe de acciones

Haleon Analyst Price Targets

Wall Street analyst price targets and consensus rating for Haleon (HLN).

Price Target Range — 3 Quarters

Analyst Consensus — 3 Analysts

3Buy

Consensus RatingOverweight# Analysts3Avg. Consensus PT$10Upside to Avg. PT+9.1%

Rating Trend — Last 9 Months

Recent Analyst Actions

View all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
Jan 23, 2026	Barclays	Warren Ackerman	Upgrade	Equal-Weight→Overweight	—
Sep 16, 2025	Barclays	Warren Ackerman	Downgrade	Overweight→Equal-Weight	—
Sep 20, 2024	Morgan Stanley	Rashad Kawan	PT Raise	Overweight	$10→$11
Mar 26, 2024	Argus Research	Taylor Conrad	Maintained	Buy	$10
Nov 1, 2023	Morgan Stanley	Rashad Kawan	Initiate	Overweight	$9

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Barclays Upgrades Haleon to Overweight

Barclays analyst Warren Ackerman upgrades Haleon (NYSE:HLN) from Equal-Weight to Overweight.

Benzinga Newsdesk

This Warner Bros. Discovery Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday

Avi Kapoor

PRO
Barclays Downgrades Haleon to Equal-Weight

Barclays analyst Warren Ackerman downgrades Haleon (NYSE:HLN) from Overweight to Equal-Weight.

Benzinga Newsdesk

What To Expect When Pfizer Outlines Its 2025 Financial Outlook On Tuesday?

Pfizer's 2025 guidance to be revealed Tuesday. Goldman Sachs predicts $64.9 billion revenue and EPS of $3.13, supported by Paxlovid and Eliquis growth.

Vandana Singh

PRO
Morgan Stanley Maintains Overweight on Haleon, Raises Price Target to $10.95

Morgan Stanley analyst Rashad Kawan maintains Haleon (NYSE:HLN) with a Overweight and raises the price target from $9.9 to $10.95.

Benzinga Newsdesk

Dr. Reddy's to Acquire Haleon's Nicotine Addiction Drug

Zacks